Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

NCT02453711 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

957

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolism and Nutrition Disorder
Obesity

Interventions

DRUG: semaglutide
DRUG: liraglutide
DRUG: placebo

Sponsor

Novo Nordisk A/S